VIAL CLARO, PABLO AGUSTIN
Thumbnail Image
Preferred name
VIAL CLARO, PABLO AGUSTIN
Main Affiliation
Email
pvial@udd.cl
ORCID
Scopus Author ID
17339613100

Research Output

2006 2006 2005 2005 2004 2004 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1.2 1.2 1.4 1.4 1.6 1.6 1.8 1.8 2.0 2.0

Filters

3
3
Reset filters

Settings
Now showing 1 - 3 of 3
No Thumbnail Available
Publication

Incubation period of hantavirus cardiopulmonary syndrome

2006-01-01 , VIAL CLARO, PABLO AGUSTIN , Valdivieso, Francisca , Mertz, Gregory , Castillo, Constanza , Belmar, Edith , DELGADO BECERRA, OROZIMBA IRIS , Tapia, Mauricio , Ferrés, Marcela

The potential incubation period from exposure to onset of symptoms was 7-39 days (median 18 days) in 20 patients with a defined period of exposure to Andes virus in a high-risk area. This period was 14-32 days (median 18 days) in 11 patients with exposure for ≤48 hours.

View
No Thumbnail Available
Publication

Peridomestic small mammals associated with confirmed cases of human hantavirus disease in Southcentral Chile

2004-01-01 , Torres-Pérez, Fernando , Navarrete-Droguett, Jorge , Aldunate, Rebeca , Yates, Terry L. , Mertz, Gregory J. , VIAL CLARO, PABLO AGUSTIN , Ferrés, Marcela , Marquet, Pablo A. , Palma, R. Eduardo

Cases of human hantavirus disease have been reported in Chile since 1995, most of them in people living in rural and periurban areas. We conducted a peridomestic study of small mammals to evaluate the relationships between the presence of rodents with antibodies to Andes virus confirmed human cases of hantavirus pulmonary syndrome in southcentral Chile. The results of 20 sampled sites, which involved the capture of 272 mice over ah 18-month period, showed the occurrence of 10 small mammal species, of which Oligoryzomys longicaudatus was the only sero-positive species for hantavirus, with an intra-specific serologic rate of 10.4%.

View
No Thumbnail Available
Publication

Hantavirus infection in children

2004-02-01 , Ferrés, Marcela , VIAL CLARO, PABLO AGUSTIN

Purpose of review: This article focuses on recent developments in knowledge about hantavirus infections and hantavirus cardiopulmonary syndrome in children. We highlight clinical characterization, epidemiology, pathogenesis, diagnostic techniques, and current alternatives for treatment and prevention. Recent findings: After the first description of hantavirus pulmonary syndrome (HPS) in 1993 in the United States, new cases of HPS and new hantavirus species have been described throughout the Americas. The factors involved in the expression of hantavirus disease have, in part, been recognized, but there have been descriptions of newer viruses and newer rodent reservoirs. Several seroprevalence studies suggest that the virus-host interaction has been taking place for many years, and changes in human behavior and wild rodent ecology, sometimes secondary to industrial progress, facilitate the clinical recognition of disease. Sin nombre virus (SNV) and Andes virus (ANDV) are examples of the same disease with differences in the virus virulence and in the host response. The North American syndrome and the Southern HPS differ in epidemiologic patterns and in the spectrum of disease. Summary: Currently, no Food and Drug Administration (FDA)-approved antiviral drugs, vaccines, or immunotherapeutic agents are available for treatment of the disease, and therapy is primarily supportive. Intensive care medicine has played an outstanding role in decreasing the lethality of HPS. A ribavirin trial in the United States did not support the use of the drug in fully developed HCPS. Recently published data suggest that a strong neutralizing antibody response may be a predictor of effective clearance of and recovery from SNV infection. This has raised the possibility that passive immunotherapy may be useful in HCPS. Extensive work has been done to develop a hantavirus vaccine, but at present it seems unlikely that a vaccine will be in commercial development in the near future.

View